Abstract
There is a pressing need for new biomarkers that can improve the care of patients with paracetamol poisoning, a common clinical problem. In this issue of Clinical Toxicology a new marker is proposed that has a number of attractive properties.
This commentary discusses the use of biomarkers in the context of the management of paracetamol-induced liver injury. New biomarkers should allow better triage and management of & “at risk” patients.